DiaSorin S.p.A. (OTCPK:DSRLF) Q4 2024 Results Conference Call March 14, 2025 12:30 PM ET
Company Participants
Carlo Rosa – CEO
Piergiorgio Pedron – CFO
Conference Call Participants
Kavya Deshpande – UBS
Maja Pataki – Kepler
Aisyah Noor – Morgan Stanley
Dylan van Haaften – Stifel
Odysseas Manesiotis – BNP Paribas
Natalia Webster – RBC Capital Markets
Jan Koch – Deutsche Bank
Shubhangi Gupta – HSBC
Operator
Good afternoon. This is the Chorus Call Conference operator. Welcome, and thank you for joining the DiaSorin Full Year 2024 Results Conference Call. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity to ask questions. [Operator Instructions]
At this time, I’ll turn the conference over to Mr. Carlo Rosa, CEO of DiaSorin. Please go ahead, sir.
Carlo Rosa
Yes. Thank you, operator. Good afternoon, and welcome to the full year conference call. We’re going to make first some comments on the full year results and then I move to the quarter four.
In 2024, revenue and profitability are in line with the planned budget and the guidance despite geopolitical tensions and macroeconomic headwinds. Specifically, when it comes to the immunoassay business, we performed very well in the main geography, U.S. and Europe, whereas, as we will see later, we continue to experience difficult situations in China, although that represents a very small portion of our revenues.
When it comes to molecular, molecular overall in the year performed better than the initial assumptions. Clearly, this for us has been a transition year because we launched successfully the LIAISON PLEX with the respiratory panel. And this better result of molecular over the year clearly compensated the LTG softer performance compared to expectations because of the life science situations, as we’ve been discussing over the last quarters.
And overall, from
Read the full article here